Annual revenue went from KRW 1.71 trillion in 2022 to KRW 1.63 trillion in 2023, down 4.9% year on year, then rose to KRW 1.68 trillion in 2024, up 3.3%, and to KRW 1.99 trillion in 2025, up 18.5%. Revenue grew for two consecutive years from 2024 to 2025, and 2025 was the largest year of 2022 to 2025.
Operating profit fell from KRW 81.3 billion in 2022 to KRW 34.4 billion in 2023, down 57.6%, and to KRW 32.1 billion in 2024, down 6.8%, before recovering to KRW 69.1 billion in 2025, up 115.4%.
The operating margin was 4.7% in 2022, 2.1% in 2023, 1.9% in 2024 and 3.5% in 2025, so the 2025 recovery did not return margins to the 2022 level.
Net income attributable to controlling shareholders was KRW 65.5 billion in 2022, turned to a net loss of KRW 26.6 billion in 2023, and remained a loss in 2024 at KRW 26.3 billion and in 2025 at KRW 4.67 billion, which means three consecutive years of losses from 2023 to 2025, with the 2025 loss narrowing sharply.
Net income including non-controlling interests was KRW 69.4 billion in 2022 and then net losses of KRW 19.8 billion, KRW 42.6 billion and KRW 29.7 billion in 2023, 2024 and 2025, a different trajectory from the controlling-shareholder figure.
Operating cash flow was KRW 119.2 billion in 2022, negative at KRW -5.47 billion in 2023 and KRW -53.5 billion in 2024, and turned to KRW 99.5 billion in 2025.
The debt-to-equity ratio rose from 61.2% in 2022 to 113.1% in 2025, with total liabilities of KRW 1.58 trillion and total equity of KRW 1.39 trillion at the end of 2025.
Quarterly results bottomed in Q4 2025, with revenue of KRW 497.8 billion, operating profit of KRW 4.6 billion and a net loss attributable to controlling shareholders of KRW 88.3 billion, before Q1 2026 returned to profit at KRW 20.5 billion.
Operating profit fell to KRW 1.73 billion in Q2 2026 and then rose to KRW 49.2 billion in Q3 2026, up 68.5% year on year, with net income attributable to controlling shareholders of KRW 222.2 billion, and the last four quarters total KRW 156.3 billion.
The company attributed the Q3 operating profit gain to influenza vaccine sales deferred from Q2, Alyglo sales growth and a narrower loss at ABO Plasma.
The jump in controlling-shareholder net income mainly reflected the Curevo deal payment, and Shinyoung Securities analyzed that a KRW 70.0 billion gain on disposal of an associate and KRW 190.0 billion in financial income related to preferred shares flowed in.